Brickell Biotech Inc

Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in September 2009 and is headquartered in Boulder, CO.

BOULDER, Colo., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell”), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, announced today the pricing of its previously announced underwritten public offering of 26,316,000 shares of its common stock at a price to the public of $0.38 per share. In addition, Brickell has granted the underwriters a 30-day option to purchase up to 3,947,400 additional shares of common stock at the public offering price, less the underwriting discount. The offering is expected to close on November 1, 2021, subject to customary closing conditions.

Brickell Biotech Prices Public Offering of Common Stock

BOULDER, Colo., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell”), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, announced today that it has commenced a proposed underwritten public offering of shares of its common stock. In connection with this offering, Brickell expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock at the public offering price, less the underwriting discount. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Brickell Biotech Announces Proposed Underwritten Public Offering of Common Stock

Digital Ally Inc

Siyata Mobile Inc.

Do these penny stocks have the potential to explode? The post Penny Stocks That Will Explode?

Penny Stocks That Will Explode? 3 For Your Watchlist

Brickell Biotech Inc (NASDAQ: BBI) has announced positive topline results from the Phase 3 pivotal Cardigan I and Cardigan II studies of sofpironium bromide gel for primary axillary hyperhidrosis (excessive underarm sweating). The Company plans to file an FDA marketing application in mid-2022.

Brickell Biotech Aces Pivotal Sofpironium Trials In Patients With Excessive Underarm Sweating

Sofpironium bromide gel, 15% was generally well-tolerated

Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance on all Primary and Secondary Endpoints, from Both U.S. Phase 3 Pivotal Clinical Studies of Sofpironium Bromide Gel, 15% in Primary Axillary Hyperhidrosis Patients

BOULDER, Colo., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, today announced that it is scheduled to host a key opinion leader (KOL) webinar on DYRK1A (Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A), which is believed to play a key role in autoimmune and inflammatory diseases, on Friday, September 24, 2021 at 10:00 a.m. EDT.

Brickell Biotech to Host Key Opinion Leader Webinar on DYRK1A and its Role in Autoimmunity

Brickell Biotech Inc (NASDAQ: BBI) has entered into a definitive agreement with Voronoi Inc for exclusive, worldwide rights to therapeutics generated from a proprietary DYRK1A inhibitor platform. The DYRK1A inhibitors aim to restore immune balance in patients whose immune system has become dysregulated, thus offering potential across a wide array of autoimmune and inflammatory diseases.

Brickell Biotech Acquires Rights To Candidate For Autoimmune Diseases

Dr. Luchi brings over 20 years of immunotherapeutic and drug development experience and will lead Brickell's clinical development strategy and medical affairs functions Dr. Luchi brings over 20 years of immunotherapeutic and drug development experience and will lead Brickell's clinical development strategy and medical affairs functions

Brickell Biotech Expands Leadership Team, Appointing Dr. Monica Luchi as Chief Medical Officer

Expect to initiate Phase 1 clinical study of lead DYRK1A inhibitor program, BBI-02, a potential first-in-class oral treatment for autoimmune and inflammatory diseases, in 2022

Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory Diseases

Brickell (BBI) delivered earnings and revenue surprises of -45.45% and 51.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Brickell (BBI) Reports Q2 Loss, Tops Revenue Estimates

Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q2 2021 Results - Earnings Call Transcript

Final patient has completed the Phase 3 pivotal Cardigan I study; Enrollment completed in Phase 3 pivotal Cardigan II study - - - Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies expected to be reported in Q4 2021 - - - Recent $8.1 million capital raise expected to fund operations beyond anticipated NDA submission in mid-2022

Brickell Biotech Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Brickell (BBI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Brickell (BBI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BOULDER, Colo., July 29, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, announced today that it will report its financial results for the second quarter, ended June 30, 2021. Brickell's management will host a conference call and webcast at 4:30 pm ET on Thursday, August 12th to discuss the financial results and recent corporate highlights.

Brickell Biotech to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on August 12, 2021

Brickell Biotech (NASDAQ: BBI) shares are trading lower after the company announced a bought deal offering of common stock of $5 million, which was later increased to $7 million. Brickell Biotech is a clinical-stage pharmaceutical company that focuses on identifying, developing, and commercialising various prescription therapeutics for the treatment of debilitating skin diseases in the United States.

Why Brickell Biotech Shares Are Trading Lower Today

The stock price of Brickell Biotech Inc (NASDAQ: BBI) fell by over 20% pre-market. This is why it happened.

BBI Stock Fell Over 20% Pre-Market: Why It Happened

BOULDER, Colo., July 19, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (the “Company” or “Brickell”), clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 11,290,323 shares of common stock of the Company at a price to the public of $0.62 per share, less underwriting discounts and commissions. The closing of the public offering is expected to occur on or about July 22, 2021, subject to satisfaction of customary closing conditions.

Brickell Biotech Increases Previously Announced Bought Deal Offering of Common Stock to $7.0 Million

BOULDER, Colo., July 19, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell” or the “Company”), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 8,064,517 shares of common stock of the Company at a price to the public of $0.62 per share, less underwriting discounts and commissions. The closing of the public offering is expected to occur on or about July 22, 2021, subject to satisfaction of customary closing conditions.

Brickell Biotech Announces $5.0 Million Bought Deal Offering of Common Stock

Topline results for Phase 3 Pivotal Cardigan I and Cardigan II studies expected in Q4 2021 Topline results for Phase 3 Pivotal Cardigan I and Cardigan II studies expected in Q4 2021

Brickell Biotech Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidro

BOULDER, Colo., June 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that the results from the Phase 3 long-term safety and efficacy study conducted in Japan by its development partner, Kaken Pharmaceutical Co., Ltd. (“Kaken”) were published in the peer-reviewed Journal of Dermatology1.

Brickell Biotech Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology

Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q1 2021 Results - Earnings Call Transcript

Shares of Brickell Biotech (NASDAQ:BBI) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 66.67% year over year to ($0.15), which missed the estimate of ($0.11).

Brickell Biotech: Q1 Earnings Insights

Completed enrollment in Phase 3 pivotal Cardigan I study and exceeded 70% enrollment in Phase 3 pivotal Cardigan II study - - - Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies expected in Q4 2021 - - - Presented results from Phase 3 open-label, long-term safety study of sofpironium bromide gel, 5% & 15% at AAD VMX 2021

Brickell Biotech Reports First Quarter 2021 Financial Results and Provides Corporate Update

BOULDER, Colo., April 29, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will report its financial results for the first quarter ended March 31, 2021, after the market close on Thursday, May 13, 2021. Brickell's management will host a conference call and webcast at 4:30 pm ET on Thursday, May 13th to discuss the financial results and recent corporate highlights.

Brickell Biotech to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13, 2021

Phase 3 Pivotal Cardigan II study exceeds 50% enrollment - - - Topline results for Phase 3 Pivotal Cardigan I and Cardigan II clinical studies expected in Q4 2021

Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

News for Brickell Biotech Inc Stock (BBI)